DK2900232T3 - Combinations and use thereof - Google Patents
Combinations and use thereof Download PDFInfo
- Publication number
- DK2900232T3 DK2900232T3 DK13766523.8T DK13766523T DK2900232T3 DK 2900232 T3 DK2900232 T3 DK 2900232T3 DK 13766523 T DK13766523 T DK 13766523T DK 2900232 T3 DK2900232 T3 DK 2900232T3
- Authority
- DK
- Denmark
- Prior art keywords
- sequence
- seq
- antibody
- melphalan
- ser
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705172P | 2012-09-25 | 2012-09-25 | |
| US201361774595P | 2013-03-08 | 2013-03-08 | |
| PCT/EP2013/069858 WO2014048921A1 (en) | 2012-09-25 | 2013-09-24 | Combinations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2900232T3 true DK2900232T3 (en) | 2018-02-05 |
Family
ID=49237209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13766523.8T DK2900232T3 (en) | 2012-09-25 | 2013-09-24 | Combinations and use thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9579378B2 (https=) |
| EP (1) | EP2900232B1 (https=) |
| JP (1) | JP6426093B2 (https=) |
| KR (1) | KR102171669B1 (https=) |
| CN (1) | CN104684552B (https=) |
| AU (1) | AU2013322806C1 (https=) |
| BR (1) | BR112015006731A2 (https=) |
| CA (1) | CA2885792C (https=) |
| DK (1) | DK2900232T3 (https=) |
| ES (1) | ES2658953T3 (https=) |
| HR (1) | HRP20171964T1 (https=) |
| HU (1) | HUE036518T2 (https=) |
| IL (1) | IL237926B (https=) |
| LT (1) | LT2900232T (https=) |
| MX (1) | MX368288B (https=) |
| NZ (1) | NZ706147A (https=) |
| PL (1) | PL2900232T3 (https=) |
| PT (1) | PT2900232T (https=) |
| RU (1) | RU2650618C2 (https=) |
| SG (1) | SG11201502163QA (https=) |
| WO (1) | WO2014048921A1 (https=) |
| ZA (1) | ZA201501980B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| MX386886B (es) | 2014-09-09 | 2025-03-12 | Janssen Biotech Inc | Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias. |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| AU2016282674B2 (en) | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| WO2017149122A1 (en) * | 2016-03-04 | 2017-09-08 | Morphosys Ag | Clinical assessment of m-protein response in multiple myeloma |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| CN113194925B (zh) * | 2018-12-14 | 2025-03-07 | 莫佛塞斯公司 | 抗体制剂 |
| EP3938394A1 (en) * | 2019-03-15 | 2022-01-19 | MorphoSys AG | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| EP3569245A1 (en) | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| DK2580243T3 (da) * | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| SI2621531T1 (sl) * | 2010-09-27 | 2017-06-30 | Morphosys Ag | Anti-cd38 protitelo in lenalidomid ali bortezomib za zdravljenje multiplega mieloma in nhl |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
-
2013
- 2013-09-24 JP JP2015532454A patent/JP6426093B2/ja active Active
- 2013-09-24 PL PL13766523T patent/PL2900232T3/pl unknown
- 2013-09-24 US US14/430,801 patent/US9579378B2/en active Active
- 2013-09-24 EP EP13766523.8A patent/EP2900232B1/en active Active
- 2013-09-24 SG SG11201502163QA patent/SG11201502163QA/en unknown
- 2013-09-24 WO PCT/EP2013/069858 patent/WO2014048921A1/en not_active Ceased
- 2013-09-24 CA CA2885792A patent/CA2885792C/en active Active
- 2013-09-24 MX MX2015003589A patent/MX368288B/es active IP Right Grant
- 2013-09-24 AU AU2013322806A patent/AU2013322806C1/en active Active
- 2013-09-24 HR HRP20171964TT patent/HRP20171964T1/hr unknown
- 2013-09-24 KR KR1020157007554A patent/KR102171669B1/ko active Active
- 2013-09-24 HU HUE13766523A patent/HUE036518T2/hu unknown
- 2013-09-24 BR BR112015006731A patent/BR112015006731A2/pt not_active Application Discontinuation
- 2013-09-24 CN CN201380050577.7A patent/CN104684552B/zh active Active
- 2013-09-24 DK DK13766523.8T patent/DK2900232T3/en active
- 2013-09-24 PT PT137665238T patent/PT2900232T/pt unknown
- 2013-09-24 LT LTEP13766523.8T patent/LT2900232T/lt unknown
- 2013-09-24 RU RU2015110981A patent/RU2650618C2/ru active
- 2013-09-24 ES ES13766523.8T patent/ES2658953T3/es active Active
- 2013-09-24 NZ NZ706147A patent/NZ706147A/en unknown
-
2015
- 2015-03-23 ZA ZA2015/01980A patent/ZA201501980B/en unknown
- 2015-03-24 IL IL237926A patent/IL237926B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2658953T3 (es) | 2018-03-13 |
| EP2900232A1 (en) | 2015-08-05 |
| IL237926B (en) | 2020-04-30 |
| SG11201502163QA (en) | 2015-04-29 |
| NZ706147A (en) | 2018-10-26 |
| AU2013322806C1 (en) | 2018-03-08 |
| HUE036518T2 (hu) | 2018-07-30 |
| US20150238603A1 (en) | 2015-08-27 |
| AU2013322806B2 (en) | 2017-11-30 |
| CN104684552A (zh) | 2015-06-03 |
| CN104684552B (zh) | 2018-08-07 |
| LT2900232T (lt) | 2018-02-26 |
| KR102171669B1 (ko) | 2020-10-30 |
| PL2900232T3 (pl) | 2018-05-30 |
| JP2015530399A (ja) | 2015-10-15 |
| CA2885792C (en) | 2021-09-28 |
| RU2015110981A (ru) | 2016-11-20 |
| ZA201501980B (en) | 2017-11-29 |
| CA2885792A1 (en) | 2014-04-03 |
| RU2650618C2 (ru) | 2018-04-16 |
| PT2900232T (pt) | 2018-02-09 |
| JP6426093B2 (ja) | 2018-11-28 |
| HRP20171964T1 (hr) | 2018-02-23 |
| MX2015003589A (es) | 2015-08-12 |
| HK1210949A1 (en) | 2016-05-13 |
| EP2900232B1 (en) | 2017-11-15 |
| US9579378B2 (en) | 2017-02-28 |
| AU2013322806A1 (en) | 2015-04-09 |
| KR20150090030A (ko) | 2015-08-05 |
| BR112015006731A2 (pt) | 2017-07-04 |
| WO2014048921A1 (en) | 2014-04-03 |
| MX368288B (es) | 2019-09-27 |
| IL237926A0 (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2900232T3 (en) | Combinations and use thereof | |
| US20240390489A1 (en) | Methods of increasing strength and functionality with gdf8 inhibitors | |
| AU2016260895B2 (en) | Treatment for multiple myeloma (MM) | |
| US11498946B2 (en) | Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients | |
| WO2025134049A1 (en) | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis | |
| TW202502813A (zh) | 包含偶聯物的藥物組合的治療方法和用途 | |
| HK1210949B (zh) | 组合及其用途 | |
| KR20250112805A (ko) | 항-ddr1 항체 및 면역관문 억제제를 사용한 암 치료 방법 | |
| KR20250115399A (ko) | 항-ddr1 항체를 사용한 암 치료 방법 | |
| KR20250112761A (ko) | 항-cd39 항체를 포함하는 암의 신보조 치료를 위한 조성물 및 방법 | |
| EA046745B1 (ru) | Способ лечения рака активируемым антителом против pdl1 | |
| HK1247939A1 (en) | Treatment for multiple myeloma (mm) | |
| NZ729207B2 (en) | Neutralization of inhibitory pathways in lymphocytes |